1-5 of 5
Pere Gascon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

Patricia Fernández-Nogueira, Mario Mancino, Gemma Fuster, Anna López-Plana, Patricia Jauregui, Vanesa Almendro, Estel Enreig, Silvia Menéndez, Federico Rojo, Aleix Noguera-Castells, Anke Bill, L. Alex Gaither, Laia Serrano, Leire Recalde-Percaz, Núria Moragas, Raul Alonso, Elisabet Ametller, Ana Rovira, Ana Lluch, Joan Albanell, Pere Gascon, Paloma Bragado
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1432–1448.
https://doi.org/10.1158/1078-0432.CCR-19-0353
Published: 13 March 2020
View article titled, Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Open the PDF for Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

Federico Rojo, Elías Gracias, Nadia Villena, Teresa Cruz, Josep Maria Corominas, Irene Corradino, Mercedes Cedeño, Clara Campas, Marta Osorio, Normando Iznaga, Beatriz Bellosillo, Ana Rovira, Silvia Marsoni, Pere Gascon, Sergio Serrano, Cristiana Sessa, Tania Crombet, Joan Albanell
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (8): 2474–2482.
https://doi.org/10.1158/1078-0432.CCR-09-3042
Published: 14 April 2010
View article titled, Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study
Open the PDF for Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study in another window
Journal Articles

Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy

Allan Lipton, Guenther G. Steger, Jazmin Figueroa, Cristina Alvarado, Philippe Solal-Celigny, Jean Jacques Body, Richard de Boer, Rossana Berardi, Pere Gascon, Katia S. Tonkin, Robert E. Coleman, Alexander H.G. Paterson, Guozhi M. Gao, Amy C. Kinsey, Mark C. Peterson, Susie Jun
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6690–6696.
https://doi.org/10.1158/1078-0432.CCR-07-5234
Published: 16 October 2008
View article titled, Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy
Open the PDF for Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy in another window
Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors

Joan Albanell, Clara Montagut, Eileen T. Jones, Linda Pronk, Begoña Mellado, Janette Beech, Pere Gascon, Gerhard Zugmaier, Michael Brewster, Mark P. Saunders, Juan W. Valle
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2726–2731.
https://doi.org/10.1158/1078-0432.CCR-07-1980
Published: 01 May 2008
View article titled, A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors in another window
Journal Articles

Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity

Josep Domingo-Domenech, Cristina Oliva, Ana Rovira, Jordi Codony-Servat, Marta Bosch, Xavier Filella, Clara Montagut, Marian Tapia, Clara Campás, Lenny Dang, Mark Rolfe, Jeffrey S. Ross, Pere Gascon, Joan Albanell, Begoña Mellado
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (18): 5578–5586.
https://doi.org/10.1158/1078-0432.CCR-05-2767
Published: 25 September 2006
View article titled, Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity
Open the PDF for Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity in another window